Application Nr Approved Date Route Status External Links
NDA020912 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Aggrastat® Is Indicated To Reduce The Rate Of Thrombotic Cardiovascular Events (Combined Endpoint Of Death, Myocardial Infarction, Or Refractory Ischemia/repeat Cardiac Procedure) In Patients With Non-St Elevation Acute Coronary Syndrome (Nste-Acs). Aggrastat Is A Platelet Aggregation Inhibitor Indicated To Reduce The Rate Of Thrombotic Cardiovascular Events (Combined Endpoint Of Death, Myocardial Infarction, Or Refractory Ischemia/repeat Cardiac Procedure) In Patients With Non-St Elevation Acute Coronary Syndrome (Nste-Acs).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Tirofiban Hydrochloride TIROFIBAN HYDROCHLORIDE ZINC3806104

Comments